Until recently, only about 60 percent of the cystic fibrosis population was eligible for CFTR modulator therapy. Now, with the approval of Trikafta, a triple-combination CFTR modulator therapy, more than 90 percent of people with CF could eventually have a highly effective therapy for the underlying cause of their disease.
Alex Gifford, MD, an associate professor of medicine and the director of the adult CF program Dartmouth-Hitchcock Medical Center, discusses ongoing clinical trials that study the effects of CFTR modulators on adults and children with cystic fibrosis, and his hopes for the future of CFTR modulator therapy.
Find a clinical trial: on.cff.org/finder
